• 1
    Akehurst R, Anderson P, Brazier J, et al. Decision analytic modeling in the economic evaluation of health technologies: a consensus statement. Pharmacoeconomics 2000;17: 44344.
  • 2
    McGuire A, Morris S. What is it to be a model? Trials and tribulations in economic evaluation. Eur J Health Econ 2000;1: 336.
  • 3
    Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: Report if the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health 2003;6: 917.
  • 4
    Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6: 21727.
  • 5
    Edmunds WJ, Medley GF, Nokes DJ. Evaluation the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999;18: 326382.
  • 6
    Weinstein MJ, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001;4: 34861.
  • 7
    Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses—a review of submissions to the Australian Pharmaceutical Benefit Scheme. JAMA 2000; 283: 211621.
  • 8
    Nuijten M, Pronk MH, Brorens MJA, et al. Reporting format for economic evaluation. II. Focus on modeling studies. Pharmacoeconomics 1998;14: 25968.
  • 9
    Sendi PP, Craig BA, Pfluger D, et al. Systematic validation of disease models for pharmacoeconomic evaluations. J Eval Clin Pract 1999;5: 28395.
  • 10
    Banz K, Wagenpfeil S, Neiss A, et al. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 2003;21: 125667.
  • 11
    Eddy D. Technology assessment: the role of mathematical modeling. In: MostellerF, ed., Assessing Medical Technologies. Washington: National Academy Press, 1985:14460.
  • 12
    McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000; 17: 50113.
  • 13
    Hodges JS, Dewar JA. Is it You or Your Model Talking? A Framework for Validation. R-4114-AF/A/OSD. Santa Monica (CA): Rand Corporation, 1992.
  • 14
    Halloran ME, Cochi SL, Lieu TA, et al. Theoretical epidemiological and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994;140: 81104.
  • 15
    Halloran ME, Watelet L, Struchiner CJ. Epidemiologic effects of vaccines with complex direct effects in an aged-structured population. Math Biosci 1994;121: 193225.
  • 16
    Wutzler P, Faerber I, Wagenpfeil S, et al. Seroprevalence of varicella-zoster virus in the German population. Vaccine 2002;20: 12124.
  • 17
    Wagenpfeil S, Neiss A, Bisanz H, et al. Epidemiology of varicella infection to assess the burden of disease in Germany. Clin Microbiol Infect (in press).
  • 18
    Wutzler P, Neiss A, Banz K, et al. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany. Med Microbiol Immunol 2002;191: 8996.
  • 19
    VIP 1998–2001. Prescription Index for Pharmaceuticals (Verschreibungsindex für Pharmazeutika). IMS, Frankfurt/Main 2002.
  • 20
    Last JM. A Dictionary of Epidemiology (3rd ed.). New York: Oxford University Press, 1995.
  • 21
    Anderson RM, Nokes DJ. Mathematical models of transmission and control. In: HollandWW, DetelsR, KnoxG, eds., Oxford Textbook of Public Health (2nd ed.). Oxford: Oxford University Press, 1991.
  • 22
    Panagiotopoulos T, Antoniado I, Valassi-Adam E. Increase in congenital rubella occurence after immunisation in Greece: retrospective survey and systematic review. BMJ 1999;319: 146267.
  • 23
    Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA 2002;287: 60611.
  • 24
    Coudeville L, Paree F, Lebrun T, et al. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999;17: 14251.
  • 25
    Huse DM, Meissner HC, Lacey MJ, et al. Childhood vaccination against chickenpox: an analysis of benefits and costs. J Pediatr 1994;124: 86974.
  • 26
    Beutels P, Clara R, Tormans G, et al. Costs and benefits of a routine varicella vaccination in German children. J Infect Dis 1996;174: 33541.
  • 27
    Diez-Domingo J, Ridao M, Latour J, et al. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 1999;17: 130611.
  • 28
    Scuffham P, Devlin N, Eberhardt-Phillips J, et al. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule. Soc Sci Med 1999;49: 76379.
  • 29
    Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 2000;18: 40715.
  • 30
    Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine 2002; 20: 111325.
  • 31
    Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994;271: 37581.